The regulatory green light is official. Aurobindo Pharma announced Saturday that the USFDA has granted final approval for its Perampanel tablets in six strengths: 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. This clears the path for the generic version of Catalyst Pharmaceuticals’ Fycompa, a drug for partial-onset seizures in patients aged four and older. The approval lands after a period of speculation, confirming the bioequivalence and therapeutic equivalence required for market entry.
Market size matters here. IQVIA MAT data pegs the US market for this specific therapy at $67 million for the 12 months ending August 2026. It’s not a blockbuster ticket, but it’s steady revenue for a generic player with distribution muscle. Aurobindo will manufacture the tablets at Unit-IV of APL Healthcare, its wholly owned subsidiary, with a commercial launch slated for Q3 of FY27. The timing suggests a quick turnaround from approval to shelf.
This nod bumps Aurobindo’s USFDA ANDA count to 599, comprising 574 final and 25 tentative approvals. Contextually, it follows a significant strategic shift: on October 1, the company launched Adquey, its first novel drug in the US, via its arm Acrotech. Adquey, a topical phosphodiesterase-4 inhibitor for atopic dermatitis, targets a much larger $1.3 billion market and carries patent protection until 2036. The dual movement—generic Perampanel plus novel Adquey—signals a balanced portfolio strategy.
The market reaction, however, was muted. Aurobindo Pharma shares closed 0.34% lower at ₹1,666.30 on the NSE on October 1. Traders seem to have already priced in the regulatory pipeline, or perhaps the focus remains on the execution of the newer, higher-stakes Adquey launch. The dedicated dermatology business unit established for Adquey now has a concurrent generic launch to manage, testing the company’s operational bandwidth in the US.
Looking ahead, the Q3 FY27 launch of Perampanel will be the next data point for analysts. With 599 ANDAs in the bank, Aurobindo’s moat is depth, but the value creation will hinge on how well it navigates the transition from pure generic volume to a mixed model that includes patented products like Adquey. The $67 million Perampanel pool is a drop in the bucket compared to the $1.3 billion dermatology opportunity, but every dollar counts in the margin business.